In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …

Glioblastoma (GBM) is the most aggressive, malignant primary brain tumor in adults. GBM is
notoriously resistant to immunotherapy mainly due to its unique immune microenvironment …

A major rate-limiting step in developing more effective immunotherapies for GBM is our
inadequate understanding of the cellular complexity and the molecular heterogeneity of …

Glioblastoma (GBM), the most common and lethal primary brain tumor, with a median
survival rate of only 15 months, remains incurable despite intensive multimodal treatment of …

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid
progenitor and precursor cells at different stages of differentiation, which play an important …

The most widely used fluorophore in glioma-resection surgery, 5-aminolevulinic acid (5-
ALA), is thought to cause the selective accumulation of fluorescent protoporphyrin IX (PpIX) …

Glioblastoma (GBM) is the most common primary malignant brain tumour in adults. Despite
the combination of novel therapeutical approaches, it remains a deadly malignancy with an …

Glioblastoma is the most aggressive malignant primary brain tumor, with a dismal prognosis
and a devastating overall survival. Despite aggressive surgical resection and adjuvant …

Glioblastoma is the most common primary brain tumor and has a dismal prognosis. The
development of central necrosis represents a tipping point in the evolution of these tumors …

Methods RNA-seq, RT-qPCR, and flow cytometry were used to determine IL15Rα
expression in paired peripheral and tumor-infiltrating immune cells of GBM patients and two …